Holding Pharmaceutical, Medical Device Executives Accountable as Responsible Corporate Officers

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, SEPTEMBER 19, 2022

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2022.4138?guestAccessKey=f1ea4abc-9bec-4039-97d7-7f12db63ce48&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091922

 

About The Study: The findings of this study suggests that federal prosecutors have exercised far less than their full capacity under the Park doctrine to sanction problematic corporate behavior that threatens patients and the public health. The objective of the doctrine is to protect patients from the harms of an unsafe or fraudulent medical marketplace by targeting the executives who run the drug or medical device companies that make revenues on these products while violating federal law, rather than have that risk borne by patients or impersonal corporate entities.

Authors: Aaron S. Kesselheim, M.D., J.D., M.P.H., of Brigham and Women’s Hospital in Boston, is the corresponding author.

 

(doi:10.1001/jamainternmed.2022.4138)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.